EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement

Jinxiong Zhang iD, Hedong Xu iD, Chunyan Tang iD, Dandan Ni, Xuyang Shen

Briefings in Bioinformatics · 04.05.2026 · 27 (3)

DOI: 10.1093/bib/bbag299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 12.06.2026. Verfasst von Jinxiong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer, Electronics and Information, Guangxi University, No. 100, Daxue East Road, Xixiangtang District, Nanning 530004, Guangxi, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Leukemia, Myeloid, Acute, Computational Biology. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: high-performance computing platform of Guangxi University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to the heterogeneity in cancer patients, accurate prediction of cancer drug response is key to achieving personalized medicine. The biological differences between cell lines and tumor tissues, as well as the domain shift caused by diverse drug mechanisms of action, make it difficult for existing methods to effectively capture the complex relationships between multimodal features. In this study, we propose a multimodal feature fusion and feature disentanglement model, named MDCDR. The model effectively integrates various modalities of drugs and cell lines. By employing an interaction-level feature disentanglement framework that integrates multi-granularity contrastive learning and feature masking prediction, we successfully achieve effective synergy between shared common patterns and specific preserved patterns at the drug–cell line interaction level. Experiments show that MDCDR significantly outperforms existing methods on benchmarks and independent clinical test sets, and exhibits good generalization to new cell lines and drugs. Furthermore, case studies on Acute Myeloid Leukemia demonstrate MDCDR’s capacity to elucidate pathway–drug associations, offering biologically interpretable guidance for precision treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsLeukemia, Myeloid, AcuteComputational BiologyHumansPrecision MedicineCell Line, TumorAlgorithms

Stichwörter der Autor:innen

cancer drug responsecontrastive learningfeature disentanglementmultimodal feature fusion

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • School of Computer, Electronics and Information, Guangxi University, No. 100, Daxue East Road, Xixiangtang District, Nanning 530004, Guangxi, China.
  • Key Laboratory of Parallel, Distributed and Intelligent Computing in Guangxi Universities and Colleges, Guangxi Center of Technology Innovation for Intelligent Digital Services, No. 100, Daxue East Road, Xixiangtang Dis…

ORCID-Profile: Jinxiong Zhang, Hedong Xu, Chunyan Tang

Förderung

  • high-performance computing platform of Guangxi University

Zitieren

APA

Zhang, J., Xu, H., Tang, C., Ni, D., & Shen, X. (2026). MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement. Briefings in Bioinformatics, 27(3). https://doi.org/10.1093/bib/bbag299

Vancouver

Zhang J, Xu H, Tang C, Ni D, Shen X. MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement. Briefings in Bioinformatics. 2026;27(3). doi:10.1093/bib/bbag299

BibTeX
@article{Zhang2026,
  author = {Zhang, Jinxiong and Xu, Hedong and Tang, Chunyan and Ni, Dandan and Shen, Xuyang},
  title = {MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement},
  journal = {Briefings in Bioinformatics},
  year = {2026},
  volume = {27},
  number = {3},
  doi = {10.1093/bib/bbag299}
}
Kostenlos starten →